ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
HORIZON KINETICS MEDICAL ETF
35.29
+0.3319
0.95%
盤後:
35.30
0.0109
+0.03%
16:10 EDT
成交量:
227
成交額:
8,052
市值:
1,658.40萬
市盈率:
- -
高:
35.30
開:
35.30
低:
35.29
收:
34.96
52周最高:
37.90
52周最低:
28.87
股本:
46.99萬
流通股本:
46.99萬
量比:
0.09
換手率:
0.05%
股息:
0.41
股息率:
1.16%
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
強生(JNJ)漲1.63% 新款雙周拋隱形眼鏡獲CE認證
金吾财讯
·
09/10
美股盤前|庫珀醫療績後跌超17%,美鷹服飾跌14%;白宮的銅關税計劃陷入停滯;美債30年期收益率創2007年來新高
老虎资讯综合
·
09/10
華東醫藥:創新藥HDM2005入選國家科技重大專項
智通财经
·
09/10
2026年國家醫保目錄談判收官:「三除外」落地,醫保商保雙軌並行,雙目錄如何重構創新藥支付邏輯
华夏时报网
·
09/10
諾華製藥(NVS.US)大股東呼籲改組董事會,以改善公司治理。此前該公司股價因連續試驗受挫於本周創下紀錄跌幅。大股東Da
智通财经
·
09/10
Artisan Partners:在藥物試驗接連受挫後 諾華應在董事會層面進行改組
格隆汇
·
09/10
信立泰重啓H股IPO,創新藥收入站上半壁江山,仍存單品依賴隱憂
蓝鲸财经
·
09/10
ETF日報(09.10)丨臨床風險事件擾動等多因素疊加,創新藥板塊回落 銀行股温和普漲
智通财经
·
09/10
透景生命(300642.SZ)控股子公司申報醫療器械註冊獲得受理
智通财经
·
09/10
東北證券:創新藥BD和商業化持續兑現 CXO超預期,傳統板塊築底拐點
智通财经
·
09/10
創新藥概念股震盪調整,百普賽斯跌超10%,萬邦醫藥、百花醫藥、千金藥業、博濟醫藥、諾思格跌超5%。
智通财经
·
09/10
中信證券:創新藥出海漸入佳境,板塊進入盈利拐點
智通财经
·
09/10
英硅智能(03696):公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組
智通财经
·
09/10
滙豐:將諾華製藥的評級上調至「持有」,目標價110瑞士法郎。
智通财经
·
09/10
艾伯維高管:穩健資產負債表與長期成長空間並存,公司可兼顧早期及晚期業務拓展機會——電話會議實錄
美股速递
·
09/09
心血管新藥研發遇困局:諾華重磅臨床折戟 Lp(a)指標降了但心血管疾病風險沒降
每日经济新闻
·
09/09
對話復宏漢霖朱儁:體系出海要拿「長線收益」,2030年創新藥收入將反超生物類似藥
新浪科技
·
09/09
對話復宏漢霖朱儁:體系出海要拿「長線收益」,2030年創新藥收入將反超生物類似藥
智通财经
·
09/09
賽諾醫療:關於參加上海證券交易所科創板2026年半年度醫療器械及醫療設備行業集體業績説明會的公告
同花顺
·
09/09
【券商聚焦】中郵證券維持翰森製藥(03692)買入評級 指創新藥成增長核心
金吾财讯
·
09/09
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/MEDX/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":35.2891,"timestamp":1789416000000,"preClose":34.9572,"halted":0,"volume":227,"hourTrading":{"tag":"盘后","latestPrice":35.3,"preClose":35.2891,"latestTime":"16:10 EDT","volume":7,"amount":247.0237,"timestamp":1789416603919,"change":0.0109,"changeRate":0.000309,"amplitude":0},"delay":0,"changeRate":0.009494467520281871,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"已收盤","change":0.3319,"latestTime":"09-14 16:00:00 EDT","open":35.3,"high":35.3,"low":35.2891,"amount":8052,"amplitude":0.000312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.9572,"sharesOutstanding":569946,"nav":34.94,"aum":16419913.24,"dividendRate":0.01159,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.3,"preClose":35.2891,"latestTime":"16:10 EDT","volume":7,"amount":247.0237,"timestamp":1789416603919,"change":0.0109,"changeRate":0.000309,"amplitude":0},"volumeRatio":0.087916},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.087916,"shares":469946,"dividePrice":0.409,"high":35.3,"amplitude":0.000312,"preClose":34.9572,"low":35.2891,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":35.2891,"eps":0,"divideRate":0.01159,"volume":227,"delay":0,"ttmEps":0,"open":35.3,"prevYearClose":33.2024,"prevWeekClose":34.9572,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":36.6906,"twentyDayClose":35.6938,"sixtyDayClose":34.2263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666596063","title":"強生(JNJ)漲1.63% 新款雙周拋隱形眼鏡獲CE認證","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596063","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 21:21","pubTimestamp":1789046500,"startTime":"0","endTime":"0","summary":"金吾财讯 | 强生(JNJ)美股盘前股价震荡上行,最新涨1.63%,报271.4美元。消息面上,强生周四宣布,旗下新款ACUVUE OASYS MAX双周抛复用隐形眼镜已拿到CE认证。该款产品属于ACUVUE OASYS MAX产品线的新品,可在完整14天佩戴周期内保障佩戴舒适度与清晰视力。镜片搭载OptiBlue滤光技术、TearStable锁泪技术以及一类紫外线防护功能,专门面向长时间使用电子屏幕人群的用眼需求设计。上市节奏方面,计划2026年晚些时候率先登陆部分欧洲国家;后续视各地监管审批进度,在2027-2028年进一步拓展市场。目前该产品尚未取得美国FDA批准,暂未在美国市场销售。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNW00.USD","LU2133065610.SGD","BMED","LU0345770993.USD","BK4581","LU0964807845.USD","JDOC","LU1066053197.SGD","IE000BZT7R73.USD","LU2505996509.AUD","LU1228905037.USD","LU2750360641.GBP","SG9999001440.SGD","XLV","PJP","IHE","TRUH","LU1929549753.HKD","IYH","RXL","LU0820562030.AUD","LU1244550494.USD","LU0345770308.USD","LU1043141396.HKD","IE00BDGV0183.EUR","LU1674673428.USD","IE00BN8TJ469.HKD","LU2750360997.AUD","LU1291159041.SGD","JNJ","LU0124676726.USD","BK4559","LU0689626769.HKD","LU1732800096.USD","VHT","BK4592","FHLC","IE00BLSP4239.USD","LU0070217475.USD","LU0792757196.USD","LU2756315318.SGD","GDOC","FTXH","MEDX","LU2456880835.USD","IE00BGHQF631.EUR","IXJ","LU2756315664.SGD","BK4532","LU0820561909.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140105110","title":"美股盤前|庫珀醫療績後跌超17%,美鷹服飾跌14%;白宮的銅關税計劃陷入停滯;美債30年期收益率創2007年來新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1140105110","media":"老虎资讯综合","labels":["AIColumn"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140105110?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 20:00","pubTimestamp":1789041651,"startTime":"0","endTime":"0","summary":"01 股市截至9月10日,美股三大期指涨跌互现。其仍保留2027年Palantir与纳指100 ETF长周期看跌合约,并进一步压缩其他头寸以降低风险暴露。该系列产品计划追踪热门美股及ETF的小时级收益倍数,为短线交易者提供新的杠杆工具。野村指出地缘政治、利率与通胀形成“负面风险三角”,推动看涨偏斜升至历史高位,市场或迎来更高波动。","market":"uk","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"AIColumn","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJTD4V19.USD","IE0009355771.USD","IE00B3T34201.USD","LU2505996681.GBP","IE00B3SWFQ91.USD","LU0359201885.HKD","LU0456854461.SGD","IE0002270589.USD","LU1261432733.SGD","LU2592432038.USD","AVEM","LU3102509885.SGD","LU0719512351.SGD","LU1119994496.HKD","LU0106261372.USD","LU0708995401.HKD","LU2471134796.USD","LU0256863902.USD","PBJ","LU1003077747.HKD","LU2461242641.AUD","LU1559883803.SGD","LU1720051108.HKD","IE00B1XK9C88.USD","LU2347655156.SGD","LU2023250330.USD","LU0345769128.USD","AIQ","IE0004445015.USD","LU0689472784.USD","IE0009G5SDU7.USD","BK4578","LU0868494617.USD","SPTE","LU1861215975.USD","TRUM","BK4579","LU2458330169.SGD","LU1923622291.USD","IE00BJLML261.HKD","DGT","LU2211814178.USD","LU1804176565.USD","LU0553294199.USD","LU0795875086.SGD","IE0034235295.USD","LU2054465674.USD","USD","LU1803068979.SGD","COPX","LU0310799852.SGD","LU1934455863.HKD","LU0511384066.AUD","BK4567","LU0075056555.USD","BK4077","LU1814569148.SGD","IE00B19Z3581.USD","LU2433249047.HKD","LU1934455277.USD","LU2456880835.USD","IE000Q6AESB8.SGD","BK4608","LU0642271901.SGD",".DJI","BREW","LU2506951792.HKD","IE0034235303.USD","BK4198","NULC","IE00B19Z3B42.SGD","LEGR","LU1116320737.USD","IE00B19Z9Z06.USD","EMSF","LU1623119135.USD","NBDS","LU0572108347.SGD","BK4007","LU1323610961.USD","LU0234570918.USD","FDTX","LU1244550494.USD","IE00BD6J9T35.USD","LU2041044095.USD","LU1244550577.SGD","LU2092937148.SGD","LU0069063385.USD","LU0345781412.USD","LU1645745479.HKD","SGXZ31699556.SGD","IE000ITXATA3.USD","LU0323591593.USD","SG9999002232.USD","LU1551013425.SGD","LU0175139822.USD","IXN","LU0878004406.USD","LU1066051225.USD","LU0823397103.USD","LU2298321311.HKD","LU2063271972.USD","LU0786609619.USD","CHAT","LU2860962120.EUR","LU0320765489.SGD","COPP","LU2092937221.SGD","LU2272731865.HKD","LU0132412106.USD","BK4529","LU0345770308.USD","LU1989772840.SGD","LU2236285917.USD","LU0094547139.USD","LU0612318385.USD","LU1718418525.SGD","CWI","LU0348723411.USD","LU0630314457.HKD","LU1202635105.USD","AIFD","BK4504","LU2065171311.SGD","IE00BJT1NW94.SGD","LU2111349929.HKD","LU2430703095.HKD","SG9999014567.USD","LU0070302665.USD","LU1974910355.USD","DISK","LU0050427557.USD","IETC","LU0310800379.SGD","LU0795875169.SGD","LU2999663052.SGD","MEDX","IE00B19Z8X17.USD","LU0210533765.USD","LU1868836757.USD","LU2896262040.SGD","LU2065169927.USD","CORO","IE00B3S45H60.SGD","ILDR","LU1282649810.SGD","LU2092627202.USD","HK0000320264.USD","LU2452424414.USD","SG9999014914.USD","LU0476273544.USD","LU0238689110.USD","LU0528227936.USD","LU0274383776.USD","LU2148611432.USD","RULE","IE00BZ9MQY76.HKD","LU2552382058.USD","FMTL","BK7094","LU0791590937.USD","IE000W1ABFV2.USD","LU1674673691.USD","LU1935043536.SGD","LU0345780950.USD","BK4610","IE00BMPRXN33.USD","LU1242518931.SGD","XTN","LU0157215616.USD","LU0081259029.USD","LU0072462426.USD","LU1066051811.HKD","CGNG","LU1691799644.USD","BK4591","LU1508157978.USD","TTEQ","SG9999002224.SGD","LU0823411888.USD","LU1066053197.SGD","SG9999014898.SGD","HK0000914660.USD","LU0943347566.SGD","BK4503","LU0823421333.USD","LU1732799900.SGD","LU0330918003.SGD","AIPI","LU0289961442.SGD","LU0823414478.USD","LU2272731600.USD","LU1366192091.USD","SG9999018857.SGD","EDZ","GB00BDT5M118.USD","LU1153585028.USD","LU1839511570.USD","LU0265550946.USD","AVSE","LU2271345857.HKD","LU0964807845.USD","LU1400636657.SGD","LU1069347547.HKD","LU1989764748.USD","BK4609","TEK","HBMX","IE00BK4W5L77.USD","AVXC","LU2048586759.USD","IE00B894F039.SGD","LU0053666078.USD","WLDR","LU0472753341.HKD","SMHX","LU1935043452.HKD","LU1430597077.USD","BOBP","IE00B775SV38.USD","LU1791710400.SGD","LU2954938101.SGD","LU0566484027.USD","IE00BKPKM429.USD","LU2462157665.USD","LU0323239441.USD","LU1366333091.USD","LU1983260115.SGD","SG9999014906.USD","LU1023059493.AUD","LU0466842654.USD","BK7016","LU0072463663.USD","LU2213496289.HKD","03145","LU2487616109.SGD","LU0444971666.USD","BK4612","IE00B2B36J28.USD","LU1923622614.USD","LU2471134952.CNY","LU1861558580.USD","LU0266512127.USD","USXF","LU2100268510.USD","LU0109391861.USD","LU0417517546.SGD","LU0342679015.USD","LU0541502299.USD","UMMA","LU1989772923.USD","BK4533","IE00BDRTCR15.USD","LU1712237335.SGD","LU0128525929.USD","IE00B7SZLL34.SGD","LU0072462343.USD","LU1267930573.SGD","LU1435385759.SGD","LU0070217475.USD","THMR","LU2430703251.USD","BK4015","BK4097","IE00BDCRKT87.USD","LU2168564222.USD","LU1883866441.USD","BK4500","EGGY","IE00BYXW3230.USD","LU1935042991.SGD","LU2381873111.SGD","LU0654597011.USD","SHOC","IE00B1BXHZ80.USD","LU0316494557.USD","LU2265009873.SGD","DDM","LU2360107168.USD","LU2089284900.SGD","SG9999004220.SGD","SG9999014880.SGD","LU0965509101.SGD","LU0820562030.AUD","LU2498475776.HKD","DIA","COPA","HK0000304797.USD","IE00B7KXQ091.USD","IE00BJJMRX11.SGD","CGIC","LU0203201768.USD","LU1127390331.HKD","SG9999014559.SGD","LU2237438978.USD","LU1720051017.SGD","LU2106854487.HKD","LU0323240290.USD","BK4103","LU2326559502.SGD","IE00BZ1G4Q59.USD","BK4598","BK4023","EMC","LU1914381329.SGD","LU0097036916.USD","09388","BLOX","SG9999002521.SGD","LU0738911758.USD","LU0210528500.USD","CNEQ","DXD","LU0056508442.USD","LU1956131251.USD","LU0661504455.SGD","EMM","LU0823414551.USD","LU0788109477.HKD","HK0000306685.HKD","LU0823431563.USD","LU0300736062.USD","LU0791591158.USD","LU1868837722.USD","LU0289739343.SGD","LU0820561909.HKD","ABFL","LU1642822529.SGD","IE00B5TLWC47.USD","LU0557290698.USD","LU2211815571.USD","SG9999014542.SGD","LU0354030438.USD","LU2417539215.USD","METV","LU2361045086.USD","ESIM","IE00BHPRN162.USD","IE00B19Z9505.USD","SGXZ51526630.SGD","LU1721428933.USD","ICOP","LU0878005551.USD","LU2403377893.USD","SG9999017495.SGD","WUGI","IE00B19Z8W00.USD","IE0004086264.USD","LU0359202008.SGD","FTXL","LFGY","LU0882574139.USD","LU0329931173.USD","IE000M9KFDE8.USD","IE00B4JS1V06.HKD","LU0823434740.USD","LU0143863784.USD","LU2237957902.USD","SDOW","LU0082616367.USD","ADVE","BK4585","LU0127658192.USD","IE00BJTD4N35.SGD","LU2756315318.SGD","IE00B4R5TH58.HKD","IE00B19Z9P08.USD","HK0000532082.HKD","LU1116320901.HKD","LU1066051498.USD","SGXZ81514606.USD","IE00BQXX3F31.USD","IE0004445239.USD","LU0868494708.USD","LU2065170008.USD","BK4548","LU2491050071.SGD","LU1868837300.USD","SG9999001424.SGD","LU0390134368.USD","LU1861220033.SGD","LU0203345920.USD","BK4527","LU2322448957.HKD","BK4605","LU0154236417.USD","LU2420271590.USD","LU0395794307.EUR","IE0005OL40V9.USD","BK4592","IE00BZ199S13.USD","IE00BQXX3D17.EUR","LU0820561818.USD","LU0861579265.USD","WISE","LU0359201612.USD","LU2237443978.SGD","LU0080751232.USD","LU0345770993.USD","LU0006306889.USD","BK4124","LU0251132253.USD","EART","LU2463028550.USD","LU0708994859.HKD","LU0792757196.USD","LU1979441026.SGD","LU2242650005.HKD","LU0329931090.USD","LU1211504680.USD","LU0143551892.USD","LU0256863811.USD","AGOX","LU2077746001.SGD","SOXQ","159571","LU2125909916.SGD","LU0354030511.USD","LU1035773651.USD","LU1064131342.USD","LU2125154935.USD","IE00BMPRXQ63.HKD","LU2347655073.USD","LU2413666699.HKD","LU2294711713.HKD","LU2394011477.USD","IE000YTNTUN2.SGD","LU2087621335.USD","ESUM","IE0002141913.USD","MEMX","LU0787776722.HKD","LU0823413587.USD","LU0823421416.USD","LU1048588211.SGD","LU1791710582.SGD","LU2083900584.USD","LU1037948541.HKD","LU1267930813.SGD","LU2602419157.SGD","LU0689626769.HKD","VT","LU2473716301.USD","LU0823413660.USD","SPWO","BK4116","LU0187121727.USD","LU0061474960.USD","BK4581","LU0109392836.USD","LU0203347892.USD","LU0950373646.USD","LU2637965513.SGD","LU2089283258.USD","IE0001KFT4U8.USD","LU0276348264.USD","LU0061475181.USD","LU2357305700.SGD","LU0788109121.HKD","LU0077335932.USD","IE00BFSS7M15.SGD","LU0942090050.USD","LU0612318971.USD","LU1629891620.HKD","LU1548497426.USD","PSI","LU0444973449.USD","LU0683600562.USD","IE00B775H168.HKD","LU0029864427.USD","LU1699723380.USD","LU2552382215.SGD","LU2552382132.HKD","LU1035775433.USD","CLSE","LU1935042215.USD","LU0158827781.USD","BK4526","LU2750360997.AUD","LU2023250504.SGD","PPH","LU0267386448.USD","CHPX","LU0300736492.USD","LU1551013342.USD","LU1878469433.USD","LU0225283273.USD","BK4535","EMET","LU1951198990.SGD","TRFK","LU0174119429.USD","LU0898699433.AUD","CGDG","LU0788109048.HKD","LU1861559042.SGD","LU0264606111.USD","IE00BN29S564.USD","LU2168563687.JPY","LU0289960550.SGD","LU0347712357.USD","LU2087625088.SGD","LU0494093205.USD","BK4551","IE000KEQY171.SGD","DOG","LU0198837287.USD","BK4588","BK4209","LU2023251221.USD","LU2065171402.SGD","LU1242518857.USD","LU2250418816.HKD","HK0000304805.HKD","BK4512","LU2237443622.USD","LU2168564495.EUR","LU2491050154.USD","LU2357627491.SGD","IE00BQXX3C00.GBP","LU2191332357.HKD","PTF","TTXU","SGXZ99366536.SGD","SG9999015978.USD","LU0985320562.USD","LU2089985449.USD","LU2746668974.SGD","LU0859254822.USD","BK4575","LU1815333072.USD","LU0726765562.USD","LU2361044949.HKD","LU2360032135.SGD","LU0965509010.AUD","LU2413666426.HKD","LU0672654240.SGD","IE0009356076.USD","LU0823431647.USD","LU0203202063.USD","SNPE","LU1732800096.USD","LU2430703178.SGD","LU2237443549.SGD","ARTY","BK4553","LU0531971165.HKD","LU2125909759.SGD","SG9999000418.SGD","SG9999014575.USD","LU0096362180.USD","IE00BWXC8680.SGD","LU1935043023.USD","BK4008","JGRO","LU1674673428.USD","LU0278409577.USD","IE00BFTCPJ56.SGD","LU0965509283.SGD","LU1815336760.USD","LU1366334651.USD","LU0061474705.USD","LU2931357623.SGD","ASIA","ROM","LU2097344357.USD","LU0488056044.USD","LU1244550221.USD","LU2168564149.EUR","LU1868838027.USD","BK4188","CMAG","LU2361044865.SGD","FTEC","LU1144417596.USD","KOMP","LU1989764664.SGD","LU2746668461.USD","SOXX","IE00B3M56506.USD","LU2360106780.USD","LU1366334578.USD","DINT","IE00BJJMRY28.SGD","LU0505663152.USD","BK4554","LU1267930730.SGD","LU1815336091.USD","LU0211328371.USD","LU0211331839.USD","LU2125154778.USD","LU1267930490.SGD","LU2322448791.USD","LU0353189680.USD","SG9999004303.SGD","LU1951200564.SGD","LU1496350502.SGD","LU2125909593.SGD","LU1400636491.USD","LU0138981039.USD","LU1923623000.USD","LU0823434583.USD","LU1571399168.USD","PICK","LU0345768740.USD","IE00B5949003.HKD","LU0572939691.SGD","LU2097344431.USD","AIS","LU0011850046.USD","GMET","LU1429558221.USD","SOXY","BK4566","CHPS","LU0266013472.USD","LU1069344957.HKD","09788","EFIV","LU1633808545.USD","LU2102340556.USD","LU0266512473.USD","LU1821325948.USD","BK4550","LU0912757837.SGD","SG9999015358.SGD","LU0345768153.USD","LU2237443465.HKD","LU0210536198.USD","ACWX","SG9999015945.SGD","IE00BMPRXR70.SGD","LU1934455194.USD","LU0133085943.USD","LU2462591350.SGD","LU0320765059.SGD","LU2756315664.SGD","IE00BJJMRZ35.SGD","LU2505996509.AUD","BAI","LU1232071149.USD","SG9999015986.USD","LU2458330243.SGD","LU1670756490.USD","LU0353189763.USD","HK0000914686.HKD","SGXZ23171101.USD","HK0000320223.HKD","LU2249611893.SGD","IE00BFSS8Q28.SGD","BK7095","LU2108987350.USD","BK4094","LU0889566641.SGD","LU2242649171.HKD","LU1084165304.USD","LU0234572021.USD","TINS","LU1868836914.USD","LU0965508806.USD","LU1868837136.USD","UDOW","VGT","LU1037948897.HKD","LU1992135472.HKD","ESLG","LU2264538146.SGD","LU2543165471.USD","IE00BKDWB100.SGD","LU1400636574.HKD","LU2168564065.EUR","FXL","LU1880398554.USD","IE0003U64NQ7.SGD","HK0000819398.USD","LU2237443382.USD","LU2247934214.USD","LU2750360641.GBP","BK4505","LU0079474960.USD","IE00BKVL7J92.USD","LU1852331112.SGD","IE00B4YYXB79.USD","SG9999015341.SGD","LU2471134879.HKD","LU0215105999.USD","LU0158827948.USD","LU0640476718.USD","LU0211327993.USD","LU1496350171.SGD","SMH","DRMY","LU0889565833.HKD","LU0265550359.USD","XNTK","LU0957808578.USD","CGGO","LU0545039389.USD","BK4602","LU0096364046.USD","LU0957791311.USD","SGXZ80539844.SGD","LU2462611646.USD","LU0124676726.USD","LU1868837565.USD","LU0757428866.USD","LU2244417387.USD","LU1316542783.SGD","HK0000306701.USD","LU2237957811.SGD","LU0107464264.USD","LU2290526834.HKD","LU1280957306.USD","SG9999015952.SGD","LU1935042488.USD","LU1917777945.USD","SG9999018865.SGD","LU2028103732.USD","LU1282649067.USD","LU1880398471.USD","LU2462591277.SGD","IE00BYQQ9H92.USD","KNOW","LU1988902786.USD","LU2133065610.SGD","LU2237443895.HKD","LU2279689827.SGD","LU2663582299.SGD","LU2047632596.USD","LU1023057109.AUD","IE00BFXG0V08.USD","LU1145028129.USD","IE00BK4W5M84.HKD","LU0979878070.USD","LU1861127337.USD","GAMR","LU2360108059.USD","LU0541501648.USD","BK4532","BK4549","LU0882747503.HKD","LU1778281490.HKD","XLK","LU0823397285.USD","LU0345769631.USD","FAI","IE00BSNM7G36.USD","LU2286300806.USD","IE0034235188.USD","TYLG","LU2491049909.HKD","LU0170899867.USD","LU0384037296.USD","SETM","BK4543","BK4141","LU2471134523.USD","IE0004091025.USD","LU2125909247.SGD","BK4534","BK4587","LU0724617625.USD","LU0057025933.USD","LU2357125470.USD","LU0308772762.SGD","BK4614","LU0572940350.SGD","LU2272731782.SGD","LU1992135399.USD","LU0949170772.SGD","BK4220","LU1868836591.USD","LU0208291251.USD","LU0048584097.USD","LU0143863198.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666602598","title":"華東醫藥:創新藥HDM2005入選國家科技重大專項","url":"https://stock-news.laohu8.com/highlight/detail?id=2666602598","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666602598?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:49","pubTimestamp":1789040985,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560028","title":"2026年國家醫保目錄談判收官:「三除外」落地,醫保商保雙軌並行,雙目錄如何重構創新藥支付邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560028","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:12","pubTimestamp":1789038763,"startTime":"0","endTime":"0","summary":"9月9日正午,北京西黄城根北街2号全国人大会议中心。最后一家参与商保创新药目录价格协商的企业代表走出大门,历时五天的2026年国家医保目录现场谈判竞价与商保创新药目录价格协商正式收官。新版国家基本医保药品目录与商保创新药目录预计今年11月公布,2027年1月1日起统一执行。五天时间里,124个目录外药品先后完成基本医保谈判竞价,12个创新药冲击商保创新药目录价格协商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870706515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870706515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","BK1161","MEDX","BK1574","LNGR","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666622025","title":"諾華製藥(NVS.US)大股東呼籲改組董事會,以改善公司治理。此前該公司股價因連續試驗受挫於本周創下紀錄跌幅。大股東Da","url":"https://stock-news.laohu8.com/highlight/detail?id=2666622025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666622025?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:25","pubTimestamp":1789035953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","MEDX","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4532","LU0211331839.USD","IE0009355771.USD","LU0070302665.USD","PPH","IE0002141913.USD","IE00BJJMRZ35.SGD","SYLD","BK4578","LU0208291251.USD","BK4588","NVS","BK4585","IE00B4R5TH58.HKD","LU0320765489.SGD","WCEO","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666562462","title":"Artisan Partners:在藥物試驗接連受挫後 諾華應在董事會層面進行改組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666562462","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666562462?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:23","pubTimestamp":1789035834,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BJJMRZ35.SGD","BK4585","BK4532","PPH","IE00B4R5TH58.HKD","LU0211331839.USD","IE0009355771.USD","LU0070302665.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","NVS","BK4578","IE00BJT1NW94.SGD","IE0002141913.USD","LU0208291251.USD","BK4588","IE00B2B36J28.USD","BK4007","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666648561","title":"信立泰重啓H股IPO,創新藥收入站上半壁江山,仍存單品依賴隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2666648561","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666648561?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 17:29","pubTimestamp":1789032552,"startTime":"0","endTime":"0","summary":"业务层面,信立泰转型取得阶段性成果的同时,核心产品收入集中的风险始终悬而未决。作为转型最重要的产品,信立坦2024 年销售额约 15 亿元,是公司创新药板块最主要的收入来源,公司创新药板块收入高度依赖这一款降压药物。虽然后续信超妥、复立坦、复立安等多款创新产品陆续获批、纳入医保,形成产品梯队,但是这些新产品体量尚小,短期内难以替代信立坦的收入贡献,公司仍然处于单品依赖阶段。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789029785904368871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0188","BK0196","BK4127","IPOS","FRHC","002294","KCE","MEDX","BK0028","BK1161","BK0239","IBBQ","BK1574","06978","BK0183","159992","BK0187","LNGR","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666693435","title":"ETF日報(09.10)丨臨床風險事件擾動等多因素疊加,創新藥板塊回落 銀行股温和普漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2666693435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666693435?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:43","pubTimestamp":1789029788,"startTime":"0","endTime":"0","summary":"临床风险事件扰动等多因素叠加,创新药板块集体回落;定增政策红利释放、中报验证盈利韧性,银行板块温和普涨。行业表现临床风险事件扰动、海外利率预期反复与资金风格轮动三重因素叠加,创新药板块集体回落。截至收盘,恒生创新药ETF华泰柏瑞跌2.93%,报1.356元;港股通创新药ETF工银跌2.67%,报1.132元;港股创新药ETF广发跌2.65%,报1.251元。截至收盘,银行AH优选ETF招商涨1.65%,报1.603元;银行ETF汇添富涨1.56%,报1.5元;银行ETF华夏涨1.39%,报1.829元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ABEQ","BK4585","DFLV","ROPE","PY","SWP","159992","BKDV","BK1574","06978","SPVM","VLUE","VUSV","VALQ","LNGR","FDN","EQRR","PRF","VMAX","BK4550","IBBQ","BK4588","CGVV","VTV","TALV","BK1161","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666755282","title":"透景生命(300642.SZ)控股子公司申報醫療器械註冊獲得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666755282","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666755282?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:50","pubTimestamp":1789012238,"startTime":"0","endTime":"0","summary":"智通财经APP讯,透景生命(300642.SZ)发布公告,公司控股子公司上海脉示生物技术有限公司申报的医疗器械注册申请于近日获得了上海市药品监督管理局的受理,产品名称:四项抗癫痫药物浓度测定试剂盒(液相色谱串联质谱法)。该产品用于检测人体血清样本中的丙戊酸、奥卡西平代谢物(10,11-二氢-10-羟基卡马西平)、托吡酯、左乙拉西坦浓度。临床上用于丙戊酸、奥卡西平代谢物(10,11-二氢-10-羟基卡马西平)、托吡酯、左乙拉西坦血药浓度的监测。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","IEIH","RSPH","HART","BK1583","159883","BK1100","300642","GDOC","AGNG","PTH","BK1574","MDEV","BK0239","LNGR","BK0046","LGHT","09996","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"東北證券:創新藥BD和商業化持續兑現 CXO超預期,傳統板塊築底拐點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666513175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下:创新药板块:海外创新药产业高景气延续,国产药企有望承接红利Pharma依托多元路径实现营收稳健增长,Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长,这与CXO板块公司的半年度业绩相印证,进一步确认了板块的中期产业趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK1161","IBBQ","BK0276","BK0028","BK1574","CXO","BK0183","000686","159992","LNGR","MEDX","06978","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666746559","title":"創新藥概念股震盪調整,百普賽斯跌超10%,萬邦醫藥、百花醫藥、千金藥業、博濟醫藥、諾思格跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666746559","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666746559?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:49","pubTimestamp":1789004940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555207","title":"中信證券:創新藥出海漸入佳境,板塊進入盈利拐點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555207","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555207?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:24","pubTimestamp":1788999885,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555270","title":"英硅智能(03696):公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555270?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:20","pubTimestamp":1788999632,"startTime":"0","endTime":"0","summary":"智通财经APP讯,英硅智能 发布公告,公司管线中领先的AI驱动候选创新药物 Rentosertib,已于北京协和医院完成III期临床试验的首例患者入组及给药;同日,上海市肺科医院亦完成了其在该试验的首例患者入组。GENESIS-IPF-3为一项评估Rentosertib用于特发性肺纤维化患者的III期临床试验。本试验旨在评估Rentosertib是否能比IIa期研究提供涵盖更大患者群体、且更长时间治疗的临床意义上的获益。Rentosertib透过抑制TNIK,旨在阻断或逆转纤维化进程,为IPF患者提供具备疾病改善潜力的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["QQQ","GK","03696","QSWN","AQGX","DQJN","NJUL","NJAN","FWD","LCLG","QQQX","AGIX","MDTX","WPAI","PSQ","NOCT","159992","TECY","IBBJ","NBDS","AIFD","161631","QID","CHAT","CWC","LNGR","AIBU","MEDX","AIQU","PSYK","06978","QQA","MVPS","TARK","CPNQ","IBBQ","GPIQ","VUSE","NEWZ","KOMP","ARTY","BMED","QMAR","QTOC","PBOT","TQQY","MFIG","OGIG","TQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666553725","title":"滙豐:將諾華製藥的評級上調至「持有」,目標價110瑞士法郎。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666553725","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666553725?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 07:44","pubTimestamp":1788997467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","IE0002141913.USD","BK4578","IE00BJT1NW94.SGD","MEDX","LU0208291251.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","NVS","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","PPH","BK4532","LU0211331839.USD","BK4588","BK4585","IE00B4R5TH58.HKD","IE0009355771.USD","FXF","LU0070302665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191303955","title":"艾伯維高管:穩健資產負債表與長期成長空間並存,公司可兼顧早期及晚期業務拓展機會——電話會議實錄","url":"https://stock-news.laohu8.com/highlight/detail?id=1191303955","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191303955?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 22:56","pubTimestamp":1788965760,"startTime":"0","endTime":"0","summary":"在近日一场备受关注的电话会议中,艾伯维公司高管明确表示,凭借其稳健的资产负债表以及充裕的长期增长跑道,公司目前能够同时审视并把握早期与晚期阶段的业务拓展契机。这一表态暗示,这家制药巨头在战略布局上拥有充分的灵活性与多元选择空间,既可着眼于处于萌芽阶段的创新资产,亦不排除对相对成熟项目的果断介入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029864427.USD","LU0234570918.USD","IE0009355771.USD","MEDX","LU2237443622.USD","LU0472753341.HKD","LU0128525929.USD","LU0661504455.SGD","RXL","LU2237443978.SGD","IE00BVYPNV92.GBP","LU1551013342.USD","BK4139","SG9999015978.USD","IE000WAW04H5.SGD","LU1496350502.SGD","IE00B2B36J28.USD","LU1496350171.SGD","LU0256863902.USD","LU0256863811.USD","LU1670628061.USD","LU0456855351.SGD","LU1236620834.HKD","BK4588","LU0289739699.SGD","LU1929549753.HKD","LU0795875086.SGD","LU0795875169.SGD","LU0861579265.USD","LU2357627491.SGD","PJP","LU2089284900.SGD","LU1023059063.AUD","LU2089283258.USD","LU1983299246.USD","LU2129689431.USD","VHT","IE0000B7K699.USD","IE00BJT1NW94.SGD","LU0553294199.USD","LU1244550221.USD","LU0124676726.USD","IE000SO60NU8.SGD","LU1934455194.USD","LU0689626769.HKD","SG9999015986.USD","LU0198837287.USD","LU1989772840.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU0069063385.USD","LU1267930573.SGD","GLAM","LU2129689605.HKD","IE00BJJMRZ35.SGD","IXJ","LU1093756168.USD","LU0820561909.HKD","IE00B3PB1722.GBP","LU1670627923.USD","LU2237443549.SGD","LU0432979614.USD","LU1267930490.SGD","IE000F7OJYX1.SGD","LU2468319806.SGD","LU0689472784.USD","LU1732800096.USD","LU2087621335.USD","XLV","BK4550","LU1923622614.USD","LU2347655073.USD","LU1236620750.USD","LU0395794307.EUR","JDOC","LU2237443895.HKD","LU0868494617.USD","SG9999003800.SGD","IE00BBT3K403.USD","LU2347655156.SGD","LU2433249047.HKD","LU0289961442.SGD","BK4581","IE0002270589.USD","LU0310799852.SGD","LU1934455863.HKD","LU2133065610.SGD","LU0289739343.SGD","LU2237443465.HKD","IE00BGHQF631.EUR","LU0859254822.USD","BK4533","SG9999015952.SGD","LU0310800379.SGD","LU0234572021.USD","LU1074936037.SGD","LU0965509101.SGD","TRUH","LU2089984988.USD","LU1061106388.HKD","IE00BVYPNW00.USD","LU0320765646.SGD","LU0965509283.SGD","LU1430594728.SGD","SG9999015945.SGD","LU1732799900.SGD","LU0823416689.USD","BK4585","LU1003077747.HKD","LU0122379950.USD","LU0114720955.EUR","BK4566","IE00B4R5TH58.HKD","LU2125909247.SGD","LU1551013425.SGD","IE00BLSP4239.USD","ABBV","LU0912757837.SGD","LU0965509010.AUD","IE00BLSP4452.SGD","LU0943347566.SGD","LU1162221912.USD","IE00BDGV0183.EUR","IE00B19Z3581.USD","LU0545039389.USD","LU1989772923.USD","IE0004445239.USD","AGNG","LU0708994859.HKD","LU0158827948.USD","LU0211327993.USD","LU1839511570.USD","LU1585245621.USD","LU0211328371.USD","BK4534","IE0002141913.USD","LU0949170772.SGD","IE00B42XCP33.USD","BK4559","LU0058720904.USD","LU1934455277.USD","SG9999001440.SGD","IE00BN8TJ469.HKD","LU1989771016.USD","IE00B19Z3B42.SGD","LU0738911758.USD","LU0868494708.USD","IE00BSNM7G36.USD","LU0203345920.USD","LU2023251221.USD","LU1718418525.SGD","LU2112291526.USD","LU2129689514.USD","SG9999011175.SGD","LU0057025933.USD","LU1244550494.USD","LU1244550577.SGD","LU0726765562.USD","LU0203347892.USD","LU0820561818.USD","IYH","LU1037948541.HKD","LU1037948897.HKD","LU0098860793.USD","LU2125909593.SGD","FTXH","LU0882574055.USD","IE000BZT7R73.USD","FHLC","LU0942090050.USD","LU2237443382.USD","LU0985320562.USD","LU1291159041.SGD","PPH","LU0417517546.SGD","LU0965508806.USD","LU0511384066.AUD","LU0170899867.USD","LU1093756325.SGD","IE000MB6IJN5.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666531862","title":"心血管新藥研發遇困局:諾華重磅臨床折戟 Lp(a)指標降了但心血管疾病風險沒降","url":"https://stock-news.laohu8.com/highlight/detail?id=2666531862","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666531862?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 22:52","pubTimestamp":1788965533,"startTime":"0","endTime":"0","summary":"9月4日,诺华与Ionis合作开发的Lp(a)〔即:脂蛋白(a)——编者注〕靶向药物pelacarsen的Lp(a)HORIZONⅢ期临床试验公布结果。这款被行业寄予厚望的候选药物,虽能大幅降低Lp(a)水平,却未能显著降低心血管事件风险,给全球心血管创新药赛道投下了一片不确定性阴影。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093869631090.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093869631090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4588","LU0320765489.SGD","MEDX","IE00BJT1NW94.SGD","BK4585","IE00B2B36J28.USD","BK4578","LU0208291251.USD","BK4007","LU0070302665.USD","BK4532","NVS","LU0211331839.USD","PPH","IE0009355771.USD","IE0002141913.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"對話復宏漢霖朱儁:體系出海要拿「長線收益」,2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666356195?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息,在2026亚布力论坛夏季年会期间,在与新浪科技的对话中,复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”,最终目的是拿到“长线收益”。营收方面,朱俊表示公司上半年实现营收35.88亿元,其中海外收入占比达19%,海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000306701.USD","BK1161","LU1992135399.USD","HK0000320264.USD","06978","LNGR","HK0000306685.HKD","HK0000165453.HKD","IE00B5TLWC47.USD","BK1574","LU2272731600.USD","PPH","XPH","HK0000320223.HKD","BK4585","LU2322448957.HKD","LU2272731782.SGD","02696","MEDX","159992","BK4588","IBBQ","IBB","LU2322448791.USD","LU2473716301.USD","LU1992135472.HKD","LU2272731865.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533226","title":"對話復宏漢霖朱儁:體系出海要拿「長線收益」,2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533226","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533226?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:54","pubTimestamp":1788958467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2322448957.HKD","MEDX","LU2473716301.USD","IBBQ","LU1992135399.USD","IE00B5TLWC47.USD","LU2272731600.USD","LU2322448791.USD","LU2272731782.SGD","BK4585","BK4588","LU1992135472.HKD","PPH","IBB","LU2272731865.HKD","LNGR","XPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582190","title":"賽諾醫療:關於參加上海證券交易所科創板2026年半年度醫療器械及醫療設備行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582190","media":"同花顺","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582190?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:39","pubTimestamp":1788950340,"startTime":"0","endTime":"0","summary":" 证券日报网讯9月9日,赛诺医疗发布公告称,公司计划于2026年9月17日15:00-17:00参加上海证券交易所组织的科创板2026年半年度医疗器械及医疗设备行业集体业绩说明 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679749361.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679749361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1574","IHI","MDEV","BK4588","BK1100","AGNG","BK0251","688108","KSTR","HART","MEDX","09996","BK4585","LNGR","PTH","XHE","RSPH","BK1583","159883","GDOC","LGHT","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458356","title":"【券商聚焦】中郵證券維持翰森製藥(03692)買入評級 指創新藥成增長核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458356","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:32","pubTimestamp":1788939161,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指,翰森制药 发布2026年中报,2026H1实现收入83.04亿元,同比增长11.7%;归母净利润42.58亿元,同比增长35.8%,利润高增部分得益于约6.31亿元的投资收益等一次性项目。创新药已成为公司增长的绝对核心。创新药收入达70.92亿元,同比增长15.4%,占总收入比重由去年同期的82.7%提升至85.4%。其中抗肿瘤领域收入54.73亿元,占总收入65.9%;非肿瘤领域收入28.31亿元,占总收入34.1%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991138","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","06978","159992","IBBQ","LNGR","03692","MEDX","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":5,"totalSize":241,"code":"91000000","status":"200"}]}}